Cue Health Inc (HLTH)

[Skyline.R8RS]

Cue management has been impressively executing on key strategic priorities beginning with exceeding the $150M cost reduction goal with $165M realized and ahead of schedule; and a number of new products in the pipeline that will provide continued test menu expansion for the Cue Health Monitoring System; and notably Flu + COVID multiplex; and Cue RSV and Cue FLU molecular tests; all under active FDA review; and with one or more approval letters anticipated in the respiratory inflection season; all on the same cartridge system platform that can be turned on immediately in Cue’s automated manufacturing system. Significantly all products are integrated into Cue Care, a same day POC solution enabling Telehealth and prescription subscription and delivery with Cue Pharmacy. At the same time leveraging Cue Lab the mail in at-home test kits, these will become very meaningful parts of the business over the next year and years beyond to profitability. With continued total revenue growth, as indicated by Q3 2023 exceeding expectations with $17.5M reported; new initiatives gaining momentum; with opportunities to bolster cash position and extend the operating runway, and various marketing channels that will offer continued commercialization and growth in 2024; the prospects of profitability looks within reach shortly thereafter!